You’re in GI questions, cruising through abdominal pain and bleeding vignettes… and then a “colon cancer risk” stem shows up with way too many plausible answer choices. This is exactly where Q-bank questions are designed to punish pattern recognition and reward mechanism + details. Let’s walk through a classic USMLE-style vignette for Lynch syndrome (HNPCC) and then dismantle every distractor the way the test writers want you to.
The Clinical Vignette (USMLE-Style)
A 43-year-old man comes to clinic for counseling about cancer screening. His father died of colon cancer at age 46. A paternal aunt had endometrial cancer at age 49. The patient has no GI symptoms. Colonoscopy performed last month shows a proximal (right-sided) colon adenocarcinoma. Tumor testing demonstrates microsatellite instability.
Which of the following is the most likely underlying mechanism?
A. APC tumor suppressor gene mutation leading to increased -catenin signaling
B. Inactivating mutation in DNA mismatch repair genes
C. Activating mutation in KRAS leading to serrated polyp formation
D. Loss of E-cadherin function causing diffuse gastric cancer and signet ring cells
E. Germline mutation in TP53 causing multiple cancers including sarcomas and breast cancer
The Correct Answer: B. Inactivating mutation in DNA mismatch repair genes
Why it’s Lynch syndrome
This stem is screaming Lynch because of:
- Early-onset colorectal cancer
- Family history of endometrial cancer
- Right-sided (proximal) colon cancer
- Microsatellite instability (MSI) on tumor testing
The mechanism (Step 1 + Step 2 relevant)
Lynch syndrome is due to germline mutation in DNA mismatch repair (MMR) genes:
- Most commonly: MLH1, MSH2
- Also: MSH6, PMS2
Loss of MMR function → replication errors accumulate, especially in repetitive DNA regions (microsatellites) → MSI-high tumors.
Key downstream concept: “Second hit”
Patients inherit one bad allele (germline), then acquire a second somatic hit → tumor formation (classic tumor suppressor logic).
What cancers are associated with Lynch?
Think: colon + endometrium + ovary, plus a few extras.
High-yield Lynch-associated cancers
- Colorectal adenocarcinoma (often right-sided, may arise from adenomas but can progress faster)
- Endometrial carcinoma
- Ovarian cancer
- Gastric and small bowel adenocarcinoma
- Hepatobiliary cancers
- Urothelial cancers (classically ureter/renal pelvis)
- Certain brain tumors (Turcot variant)
How USMLE Tests Lynch: The “Tell” Features
Clinical clues
- Age <50 with colorectal cancer
- Multiple relatives with related cancers
- Endometrial cancer in the pedigree
- Right-sided tumor
- Synchronous/metachronous colorectal cancers (multiple primaries over time)
Path/lab clues
- MSI-high on PCR testing
- Loss of MMR protein expression on immunohistochemistry (IHC)
IHC nuance (often Step 2-ish):
- Loss of MLH1 can be sporadic (via promoter hypermethylation), so additional testing (e.g., BRAF mutation) may help distinguish sporadic MSI from Lynch depending on the exact question.
Why Every Other Answer Choice Is Wrong (and What It Really Describes)
A. APC mutation → increased -catenin signaling (Wrong)
This is the classic pathway for FAP and many sporadic colorectal cancers.
What it actually describes
- Familial adenomatous polyposis (FAP): germline APC mutation (chromosome 5q)
- Hundreds to thousands of adenomatous polyps
- Near-inevitable colorectal cancer if untreated
Clues you’d expect instead
- Teen/young adult with numerous polyps
- Extraintestinal findings:
- Desmoid tumors
- Osteomas
- Congenital hypertrophy of retinal pigment epithelium (CHRPE)
- Dental abnormalities
(Often grouped under Gardner variant)
Why it’s not Lynch
- Lynch: few polyps, rapid progression, MMR defect/MSI
- FAP: massive polyp burden, APC/Wnt pathway
C. KRAS mutation leading to serrated polyp formation (Wrong)
KRAS is a real player in colorectal carcinogenesis, but this answer is mixing pathways in a way that’s meant to trap you.
What’s true and testable
- The classic adenoma-carcinoma sequence often includes:
- APC loss (early)
- KRAS activation (intermediate)
- p53 loss (late)
Serrated pathway nuance
- Many sessile serrated lesions are associated with BRAF, CpG island methylation, and sometimes MSI (via MLH1 promoter hypermethylation in sporadic cases).
- KRAS can be seen in some serrated lesions, but for USMLE, Lynch = germline MMR defect is the clean mechanism.
Why it’s not Lynch
- Lynch is defined by inherited MMR gene mutation, not KRAS-driven serrated biology.
D. Loss of E-cadherin → diffuse gastric cancer with signet ring cells (Wrong)
This is classic hereditary diffuse gastric cancer (and also a theme in lobular breast cancer).
What it actually describes
- CDH1 mutation → loss of E-cadherin
- Leads to diffuse-type gastric adenocarcinoma
- Signet ring cells
- “Linitis plastica” (leather bottle stomach)
Clues you’d expect instead
- Gastric cancer in multiple relatives
- Early-onset diffuse gastric cancer
- Not specifically tied to MSI or right-sided colon cancer
E. Germline TP53 mutation → Li-Fraumeni syndrome (Wrong)
This one is a favorite “big cancer syndrome” distractor.
What it actually describes
- Li-Fraumeni syndrome: germline TP53 mutation
- Broad cancer risk, classically:
- Sarcomas
- Premenopausal breast cancer
- Brain tumors
- Adrenocortical carcinoma
- Leukemia
Clues you’d expect instead
- Multiple family members with diverse early cancers (not specifically colon + endometrial)
- Not a microsatellite instability story
Quick Compare Table (High-Yield)
| Syndrome | Gene/Defect | Inheritance | Hallmark Clue | Key Cancers/Findings |
|---|---|---|---|---|
| Lynch (HNPCC) | MMR genes (MLH1, MSH2, MSH6, PMS2) → MSI | AD | Right-sided colon cancer + endometrial cancer history | CRC, endometrial, ovarian, gastric, urothelial |
| FAP | APC (Wnt/-catenin) | AD | Hundreds–thousands of adenomas | CRC + extracolonic tumors (desmoids, osteomas, CHRPE) |
| Li-Fraumeni | TP53 | AD | Many early cancers across organs | Sarcoma, breast, brain, adrenal cortex, leukemia |
| Hereditary diffuse gastric cancer | CDH1 (E-cadherin) | AD | Diffuse gastric ca, signet rings | Linitis plastica, lobular breast ca association |
How This Shows Up in Real USMLE Questions
Common question formats
- “Which gene is mutated?” → MMR genes
- “What test result is expected?” → MSI-high, loss of MMR proteins on IHC
- “Which additional cancer screening is important?” → endometrial/ovarian considerations in women, and earlier/more frequent colonoscopy
High-yield management pearls (Step 2 flavored)
- Suspected Lynch based on family history → evaluate using clinical criteria (often referenced) and confirm with tumor testing (MSI/IHC) + germline testing.
- Colon cancers in Lynch can occur earlier and can be proximal → colonoscopy starts earlier and is more frequent than average-risk screening.
(If your Q-bank asks for exact ages/intervals, pick the choice reflecting early and frequent colonoscopy rather than “start at 45 like average risk.”)
Takeaway: The One-Sentence Pattern
Lynch = autosomal dominant germline mismatch repair defect → microsatellite instability → early right-sided colon cancer + endometrial cancer in the family.
When you see MSI in a colon tumor and a pedigree with endometrial cancer, don’t overthink it—then use the distractors to prove to yourself why it’s not APC/FAP, TP53/Li-Fraumeni, or CDH1/diffuse gastric.